сунитинибтаргетная терапияметастатический рак почки1.1. Keane T., Gillatt D., Evans C. P., Tubaro A. Current and future trends in treatment of renal cancer. Eur Urol Suppl 2007;6:374—84.Keane T., Gillatt D., Evans C. P., Tubaro A. Current and future trends in treatment of renal cancer. Eur Urol Suppl 2007;6:374—84.2.2. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2007 году. М., 2008.Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2007 году. М., 2008.3.3. Cohen H.T., McGovern F.J. Renal-cell carcinoma. N Engl J Med 2005;353:2477—90.Cohen H.T., McGovern F.J. Renal-cell carcinoma. N Engl J Med 2005;353:2477—90.4.4. Hamdy F.C. Management of urologic malignancies. N Engl J Med 2002;247:325—9.Hamdy F.C. Management of urologic malignancies. N Engl J Med 2002;247:325—9.5.5. Ljungberg B., Hanbury D.C., Kuczyk M.A. et al. Guidelines on renal cell cancer. Eur Urol 2007;51:1502—10.Ljungberg B., Hanbury D.C., Kuczyk M.A. et al. Guidelines on renal cell cancer. Eur Urol 2007;51:1502—10.6.6. Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983—1993. Semin Oncol 1995;22:42—60.Yagoda A., Abi-Rached B., Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983—1993. Semin Oncol 1995;22:42—60.7.7. Eisen T., Christmas T. Сlinical progress in renal cancer. London, 2007.Eisen T., Christmas T. Сlinical progress in renal cancer. London, 2007.8.8. Motzer R.J., Masumdar M., Bacic J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530—40.Motzer R.J., Masumdar M., Bacic J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530—40.9.9. Motzer R.J., Bacik J., Murphy B.A. et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289—96.Motzer R.J., Bacik J., Murphy B.A. et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289—96.10.10. Mulders P. Continued progress in treatment of advanced renal cell carcinoma: an update on the role of Sunitinib. Eur Urol Suppl 2008;7:579—84.Mulders P. Continued progress in treatment of advanced renal cell carcinoma: an update on the role of Sunitinib. Eur Urol Suppl 2008;7:579—84.11.11. Трапезникова М.Ф., Глыбин П.А., Морозов А.П. и др. Ангиогенные факторы при почечно-клеточном раке. Онкоурология 2008;(4):82—7.Трапезникова М.Ф., Глыбин П.А., Морозов А.П. и др. Ангиогенные факторы при почечно-клеточном раке. Онкоурология 2008;(4):82—7.12.12. Motzer R.J., Michaelson M.D., Redman B.G. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16—24.Motzer R.J., Michaelson M.D., Redman B.G. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16—24.13.13. Motzer R.J., Rini B.I., Bukowski R.M. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516—24.Motzer R.J., Rini B.I., Bukowski R.M. et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516—24.14.14. Motzer R.J., Michaelson M.D., Rosenberg J. et al, Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007;178:1883—7.Motzer R.J., Michaelson M.D., Rosenberg J. et al, Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007;178:1883—7.15.15. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115—24.Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115—24.16.16. Figlin R.A., Hutson T.E., Tomczak P. et al. Overall survival with Sunitinib versus interferon-alfa (IFN-) as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008;26(Suppl):256. Abstr. 5024.Figlin R.A., Hutson T.E., Tomczak P. et al. Overall survival with Sunitinib versus interferon-alfa (IFN-) as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008;26(Suppl):256. Abstr. 5024.17.17. Motzer R.J., Michaelson M.D., Hutson T.E. Sunitinib versus interferon alfa as first-line treatment of metastatic renalcell carcinoma: updated efficacy and safety results and further analysis of prognostic factors. Eur J Cancer Suppl 2007;5:301. Abstr. 4509.Motzer R.J., Michaelson M.D., Hutson T.E. Sunitinib versus interferon alfa as first-line treatment of metastatic renalcell carcinoma: updated efficacy and safety results and further analysis of prognostic factors. Eur J Cancer Suppl 2007;5:301. Abstr. 4509.18.18. Kollmannsberger C., Soulieres D., Wong R. et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Ass J 2007;1(2 Suppl):41—54.Kollmannsberger C., Soulieres D., Wong R. et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Ass J 2007;1(2 Suppl):41—54.19.19. Gore M., Szczylik C., Porta C. et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of safety and efficacy in an expanded access trial with subpopulation analysis. Eur J Cancer Suppl 2007;5:299. Abstr. 4503.Gore M., Szczylik C., Porta C. et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of safety and efficacy in an expanded access trial with subpopulation analysis. Eur J Cancer Suppl 2007;5:299. Abstr. 4503.20.20. Patard J.-J. Tyrosine kinase inhibitors in clinical practice: patient selection. Eur Urol Suppl 2008;7:601—9.Patard J.-J. Tyrosine kinase inhibitors in clinical practice: patient selection. Eur Urol Suppl 2008;7:601—9.21.21. Roigas J. Clinical management of patients receiving tyrosine kinase inhibitors for advanced renal cell carcinoma. Eur Urol Suppl 2008;7:593—600.Roigas J. Clinical management of patients receiving tyrosine kinase inhibitors for advanced renal cell carcinoma. Eur Urol Suppl 2008;7:593—600.